Dopamine agonists and valvular heart disease

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 4, 2009, Pages 316-320

  Cheung, Dianne ^a   Heaney, Anthony ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cabergoline; Cardiac valve disease; Dopamine agonists; Prolactinomas

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; SEROTONIN 2B RECEPTOR;

CLINICAL PRACTICE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HIGH RISK PATIENT; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; LOW DRUG DOSE; MEDICAL LITERATURE; MITRAL VALVE REGURGITATION; NAUSEA; PARKINSON DISEASE; PROLACTINOMA; REVIEW; TREATMENT DURATION; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE; VOMITING;

DOPAMINE AGONISTS; HEART VALVE DISEASES; HUMANS; PITUITARY NEOPLASMS; PROLACTINOMA;

EID: 67651122085     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32832d9f64     Document Type: Review

References (27)

1. Vance ML, Evans WS, Thorner MO. Drugs five years later: bromocriptine. Ann Intern Med 1984; 100:78-91.
2. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. JCEM 1985; 60:698-705.
3. Freda PU, Andreadis CI, Khandji AG, et al. Long-term treatment of prolactinsecreting macroadenomas with pergolide. JCEM 2000; 85:8-13.
4. Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naïve patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. JCEM 2000; 85:2247-2252. (Pubitemid 32269250)
5. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. NEJM 2007; 356:29-38. (Pubitemid 46041751)
6. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. NEJM 2007; 356:39-46. (Pubitemid 46041752)
7. Colao A, Galderisi M, Sarno A, Pardo M, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. JCEM 2008; 93:3777-3784. This paper is the first study that showed increased moderate tricuspid regurgitation in patients being treated with the dopamine agonist (cabergoline) for prolactinomas. It highlights that the risk of cardiac valve disease is not limited to dopamine agonist use in Parkinson's disease.
8. Steiger M, Jost W, Grandas F, Van Camp F. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J Neural Transm 2009; 116:179-191. A recent review that illustrates that the use of ergot-derived dopamine agonists (cabergoline and pergolide) in patients with Parkinson's disease is associated with increased risk of cardiac valve regurgitation, but not with the use of nonergot dopamine agonists. This observation may have important clinical significance, in supporting the use of nonergot dopamine agonist, to avoid the adverse effect of cardiac valve disease.
9. Nichols DE, Nichols CD. Serotonin receptors. Chem Rev 2008; 108:1614-1641.
10. Roth BL. Drugs and valvular heart disease. NEJM 2007; 356:6-9.
11. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. NEJM 1997; 337:581-588. (Pubitemid 27360757)
12. Setola V, Hufeisen S, Grande-Allen J, et al. 3,4- Methylenedioxymethamphetamine (MDMA, 'Ecstasy') induces fenfluramine-like proliferation actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003; 63: 1223-1229.
13. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007; 6:826-829. (Pubitemid 47243713)
14. Serratrice J, Disdier P, Habib G, et al. Valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 2002; 10:334-446. (Pubitemid 35266254)
15. Hofmann C, Penner U, Dorow R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5- HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006; 29:80-86. (Pubitemid 44357157)
16. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27:485-534.
17. Kars M, Pereira M, Bax JJ, Romijn JA. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur Endocrinol 2008; 159:363-367. This review illustrates that although there have beenmany studies showing significant cardiac valve regurgitation in patients with Parkinson's disease on cabergoline (eight studies), only one of six studies in cabergoline-treated patients for prolactinomas reported significant moderate regurgitation. The authors emphasized that in prolactinoma patients requiring higher cumulative doses and longer duration of treatment, evaluation with echocardiograms should be considered.
18. Yamashiro K, Komine-Kobayashi M, Hatano T, et al. The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 2008; 23:935-941.
19. Lancellotti P, Livadariu E, Markov M, et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008; 159:1-5. (Pubitemid 351969123)
20. Bogazzi F, Buralli S, Manetti L, et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinemia. Int J Clin Pract 2008; 62:1864-1869.
21. Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2008. PMID: 18594989. [Epub ahead of print]
22. Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. JCEM 2008; 93:3348-3356.
23. Wakil A, Rigby AS, Clark AL, et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocr 2008; 159:R11-R14.
24. Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrin 2009; 70:104-108. The results of this study show that the commonly used doses of cabergoline (0.25-3 mg/week) to treat prolactinomas were not associated with significant valvulopathy.
25. Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment in prolactinomas of 150 patients. JCEM 2008; 93:4721-4727. This study reports that of 150 patients on cabergoline, 84% of patients achieved normalization of prolactin at 3 mg/week, reaching 97.3% at doses of 9 mg/week, with complete normalization in the entire group at doses of 11 mg/week.
26. Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. JCEM 2001; 86:5256-5261. (Pubitemid 33070245)
27. Molitch ME. The cabergoline-resistant prolactinoma patient: new challenges. JCEM 2008; 93:4643-4645. This editorial reviews the literature on cardiac valvulopathy risk in cabergoline-treated patients and concludes that conventional doses (≤2 mg/week) are not likely to increase the risk of valvular disease.